March 16, 2020
Novo Nordisk Pharma said on March 13 that it has obtained Japanese approval for three types of single-dose subcutaneous devices for its once-weekly GLP-1 agent Ozempic (semaglutide), which has been pending listing since its approval two years ago. Ozempic was...read more